Motixafortide, sold under the brand name Aphexda, is an antineoplastic medication used in the treatment of multiple myeloma. It works as a hematopoietic stem cell mobilizer and CXCR4 antagonist, given by subcutaneous injection in combination with the growth factor filgrastim to move blood-forming stem cells out of the bone marrow and into the bloodstream, where they can be collected for use in an autologous stem cell transplant. It is indicated specifically to mobilize these stem cells for collection and subsequent transplantation in multiple myeloma patients. The United States Food and Drug Administration approved motixafortide in September 2023, based on evidence from the GENESIS clinical trial, which enrolled 122 multiple myeloma patients across twenty-one sites in five countries. It is developed by BioLineRx Ltd.
Facts
Classification
Approval Status ATC ClassSourced to the subject's own accountL: Antineoplastic and Immunomodulating Agents 2 Route of Administration First Approved / Isolated Year Sources
1. Motixafortide (Wikipedia)
Lead section, approval-status statementQuote, Lead section, approval-status statement
Motixafortide was approved for medical use in the United States in September 2023.
2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code LQuote, First-level anatomical group codes, Code L
Antineoplastic and immunomodulating agents
3. Wikipedia
Wikipedia contributors, Wikimedia Foundationhttps://en.wikipedia.org/wiki/Motixafortide, lead sectionQuote, https://en.wikipedia.org/wiki/Motixafortide, lead section
tic stem cell mobilizer and a CXCR4 antagonist. It is given by subcutaneous injection.
4. Drugs.com: Aphexda (motixafortide) FDA Approval History
FDA Approval HistoryQuote, FDA Approval History
Aphexda (motixafortide) was first approved by the FDA on September 8, 2023
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.